StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)

Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –

Neurocrine Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Neurocrine Biosciences's operating income for the twelve months ending Jun 30, 2026 was $794.80M, up 60.6% year over year. For fiscal 2025 it was $619.10M, up 8.5% from the year before. The highest annual figure on record is $619.10M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$619.10M+8.5%
FY2024Dec 31, 2024$570.50M+127.4%
FY2023Dec 31, 2023$250.90M+0.8%
FY2022Dec 31, 2022$249.00M+142.9%
FY2021Dec 31, 2021$102.50M-37.1%
FY2020Dec 31, 2020$163.00M+125.4%
FY2019Dec 31, 2019$72.30M+96.5%
FY2018Dec 31, 2018$36.80M–
FY2017Dec 31, 2017-$131.36M–
FY2016Dec 31, 2016-$147.37M–
FY2015Dec 31, 2015-$94.20M–
FY2014Dec 31, 2014-$64.41M–
FY2013Dec 31, 2013-$49.68M-3530.8%
FY2012Dec 31, 2012$1.45M-95.7%
FY2011Dec 31, 2011$33.92M–
FY2010Dec 31, 2010-$13.72M–
FY2009Dec 31, 2009-$53.67M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$151.50M+4.1%
Q1 FY2026Mar 31, 2026$193.40M+719.5%
Q4 FY2025Dec 31, 2025$210.90M+48.5%
Q3 FY2025Sep 30, 2025$239.00M+30.0%
Q2 FY2025Jun 30, 2025$145.60M+0.1%
Q1 FY2025Mar 31, 2025$23.60M-76.2%
Q4 FY2024Dec 31, 2024$142.00M-5.5%
Q3 FY2024Sep 30, 2024$183.80M+30.2%
Q2 FY2024Jun 30, 2024$145.40M+97.6%
Q1 FY2024Mar 31, 2024$99.30M–
Q4 FY2023Dec 31, 2023$150.30M+45.4%
Q3 FY2023Sep 30, 2023$141.20M+60.8%
Q2 FY2023Jun 30, 2023$73.60M+34.6%
Q1 FY2023Mar 31, 2023-$114.20M-3783.9%
Q4 FY2022Dec 31, 2022$103.40M–
Q3 FY2022Sep 30, 2022$87.80M+97.3%
Q2 FY2022Jun 30, 2022$54.70M-12.9%
Q1 FY2022Mar 31, 2022$3.10M-90.2%
Q4 FY2021Dec 31, 2021-$36.30M-150.6%
Q3 FY2021Sep 30, 2021$44.50M–
Q2 FY2021Jun 30, 2021$62.80M-18.0%
Q1 FY2021Mar 31, 2021$31.50M-46.5%
Q4 FY2020Dec 31, 2020$71.80M+47.1%
Q3 FY2020Sep 30, 2020-$44.30M-149.2%
Q2 FY2020Jun 30, 2020$76.60M+122.7%
Q1 FY2020Mar 31, 2020$58.90M–
Q4 FY2019Dec 31, 2019$48.80M+124.1%
Q3 FY2019Sep 30, 2019$90.10M+65.9%
Q2 FY2019Jun 30, 2019$34.40M–
Q1 FY2019Mar 31, 2019-$101.00M–
Q4 FY2018Dec 31, 2018$21.78M+84.0%
Q3 FY2018Sep 30, 2018$54.32M–
Q2 FY2018Jun 30, 2018-$1.85M–
Q1 FY2018Mar 31, 2018-$37.45M–
Q4 FY2017Dec 31, 2017$11.83M–
Q3 FY2017Sep 30, 2017-$6.00M–
Q2 FY2017Jun 30, 2017-$57.27M–
Q1 FY2017Mar 31, 2017-$79.93M–
Q4 FY2016Dec 31, 2016-$46.25M–
Q3 FY2016Sep 30, 2016-$38.44M–

More Neurocrine Biosciences figures

See a number that looks wrong?